1. ALLA AKTIER
  2. NYHETER
  3. VITROLIFE

Vitrolife

Nyheter Vitrolife Nyheter alla bolag

Interim report Q2, 2025: Strong performance across Consumables

REG

Second quarter

  • Sales of SEK 871 (941) million, a flat growth in local currencies and a 7% decrease in SEK, due to a significant currency impact of -8%. Organic growth in local currencies excluding discontinued business was 3%.
  • Sales per region, in local currencies was -3% in EMEA, +5% excluding discontinued business, +5% in Americas and 0% in APAC.
  • Sales per product group, in local currencies excluding discontinued business was +9% in Consumables, -6% in Technologies and +3% in Genetics.
  • Sales per product group, in local currencies was +5% in Consumables, -8% in Technologies and 0% in Genetics.
  • Gross margin decreased to 58.0% (59.9) also negatively impacted by currency.
  • Earnings before depreciation and amortisation (EBITDA) decreased to SEK 243 (327) million, resulting in an EBITDA margin of 27.8% (34.7), significantly impacted by negative currency effect.
  • Operating cash flow amounted to SEK 151 million (236).
  • Net income was SEK 100 (143) million, resulting in earnings per share of SEK 0.74 (1.06).
  • Vitrolife AB (publ) acquired a leading stake in AutoIVF.

First half year

  • Sales of SEK 1,714 (1,782) million, a flat growth in local currencies and a 4% decrease in SEK, due to a significant currency impact of -4%. Organic growth in local currencies excluding discontinued business was 3%.
  • Sales per region, in local currencies was +2% in EMEA, +10% excluding discontinued business, +7% in Americas and -8% in APAC.
  • Sales per product group, in local currencies excluding discontinued business was +7% in Consumables, -6% in Technologies and +4% in Genetics.
  • Sales per product group, in local currencies was +4% in Consumables, -7% in Technologies and +1% in Genetics.
  • Gross margin decreased to 57.7% (58.6) also negatively impacted by currency.
  • Earnings before depreciation and amortisation (EBITDA) decreased to SEK 500 (600) million, resulting in an EBITDA margin of 29.2% (33.6), significantly impacted by negative currency effect.
  • Operating cash flow amounted to SEK 220 million (434).
  • Net income was SEK 199 (258) million, resulting in earnings per share of SEK 1.48 (1.91).

Gothenburg, July 17, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 17-07-2025 08:00 CET.

Datum 2025-07-17, kl 08:00
Källa Cision
Bifogade filer
Interim report Q2, 2025
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!